Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: eribulin
Sponsor: Dana-Farber Cancer Institute
Collaborators: Eisai Inc.|Genentech, Inc.